Renal denervation in human hypertension: Mechanisms, current findings, and future prospects

Current Hypertension Reports

Volumn 14, Issue 3, 2012, Pages 247-253

  Schlaich, Markus P ^a   Hering, Dagmara ^a   Sobotka, Paul A ^b   Krum, Henry ^c   Esler, Murray D ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Activation; Blood pressure; Cardiovascular; Glucose metabolism; Hypertension; Left ventricular hypertrophy; Renal denervation; Renal disease; Renal failure; Renal nerve ablation; Sympathetic

Indexed keywords

ANTIHYPERTENSIVE AGENT; CLONIDINE; MOXONIDINE;

ABLATION THERAPY; ADRENERGIC ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; CLINICAL EFFECTIVENESS; COMORBIDITY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DENERVATION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY INNERVATION; KIDNEY NERVE; MICROALBUMINURIA; MINIMALLY INVASIVE PROCEDURE; NEPHRECTOMY; NONHUMAN; OBESITY; PATIENT COMPLIANCE; PATIENT SAFETY; RADIOFREQUENCY ABLATION; REINNERVATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURGICAL APPROACH; SURGICAL RISK; SYMPATHECTOMY; SYMPATHETIC INNERVATION; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

DENERVATION; HUMANS; HYPERTENSION; KIDNEY; SYMPATHECTOMY;

EID: 84865679012     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0264-9     Document Type: Article

References (59)

1. Barajas L. Innervation of the renal cortex. Fed Proc. 1978;37 (5):1192-201. (Pubitemid 8314398)
2. Bell-Reuss E, Trevino DL, Gottschalk CW. Effect of renal sympathetic nerve stimulation on proximal water and sodium reabsorption. J Clin Invest. 1976;57(4):1104-7.
3. Kirchheim H, Ehmke H, Persson P. Sympathetic modulation of renal hemodynamics, renin release and sodium excretion. Klin Wochenschr. 1989;67(17):858-64. (Pubitemid 19208123)
4. Kon V. Neural control of renal circulation. Miner Electrolyte Metab. 1989;15(1-2):33-43. (Pubitemid 19013523)
5. Zanchetti AS. Neural regulation of renin release: experimental evidence and clinical implications in arterial hypertension. Circulation. 1977;56(5):691-8. (Pubitemid 8235170)
6. Campese VM. Neurogenic factors and hypertension in chronic renal failure. J Nephrol. 1997;10(4):184-7. (Pubitemid 27333193)
7. Ye S, et al. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens. 1998;11(6 Pt 1):723- 8. (Pubitemid 28313692)
8. Ye S, et al. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens. 2002;15(8):717-24. (Pubitemid 34804278)
9. Campese VM. Neurogenic factors and hypertension in renal disease. Kidney Int. 2000;57 Suppl 75:S2-6. (Pubitemid 30205432)
10. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension. 1995;25(4 Pt 2):878-82.
11. Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis. 1995;26(5):861-5.
12. DiBona GF. Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens. 2002;11(2):197-200. (Pubitemid 34194740)
13. DiBona GF. Neural control of the kidney: past, present, and future. Hypertension. 2003;41(3 Pt 2):621-4. (Pubitemid 36314564)
14. Esler M, et al. Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol. 1986;8 Suppl 5:S39-43. (Pubitemid 16039090)
15. Schlaich MP, et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension. 2004;43(2):169-75. (Pubitemid 38174169)
16. Esler M, Jennings G, Lambert G. Noradrenaline release and the pathophysiology of primary human hypertension. Am J Hypertens. 1989;2(3 Pt 2):140S-6S. (Pubitemid 19082354)
17. Hasking GJ, et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73 (4):615-21. (Pubitemid 16081418)
18. Aggarwal A, et al. Regional sympathetic effects of low-dose clonidine in heart failure. Hypertension. 2003;41(3):553-7. (Pubitemid 36314631)
19. Petersson M, et al. Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J. 2005;26(9):906-13. (Pubitemid 40676571)
20. DiBona GF. The sympathetic nervous system and hypertension: recent developments. Hypertension. 2004;43(2):147-50. (Pubitemid 38174164)
21. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77(1):75-197. (Pubitemid 27069290)
22. Alexander BT, et al. Renal denervation abolishes hypertension in low-birth-weight offspring from pregnant rats with reduced uterine perfusion. Hypertension. 2005;45(4):754-8. (Pubitemid 40418377)
23. Kassab S, et al. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension. 1995;25(4 Pt 2):893-7.
24. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953;152 (16):1501-4.
25. Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet. 1953;1 (6757):403-8.
26. Krum H, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275-81. This study presents the first data on the safety and efficacy of a novel catheter based approach to functionally denervate the human kidney demonstrating a favorable safety profile and substantial and sustained reductions blood pressure.
27. Esler MD, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903-9. Initial proof-of-concept studies are now supported by this first randomized controlled clinical trial demonstrating that compared to an untreated control group there is substantial BP reduction associated with renal denervation.
28. Schlaich MP, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361(9):932-4. This study reports on a patient treated with catheter based renal nerve ablation demonstrating a reduction in central sympathetic outflow indicative of a potential involvement of afferent nerve fibers in the sustained blood pressure reduction associated with the procedure and additional benefit by regression of LV hypertrophy.
29. Kline RL, Mercer PF. Functional reinnervation and development of supersensitivity to NE after renal denervation in rats. Am J Physiol. 1980;238(5):R353-8.
30. Arrowood JA, et al. Evidence against reinnervation of cardiac vagal afferents after human orthotopic cardiac transplantation. Circulation. 1995;92(3):402-8.
31. Catheter-based renal sympathetic denervation for resistant hypertension. durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911-7. This study demonstrates that the blood pressure effects achieved by renal denervation are sustained up to at least 2 years.
32. Lambert GW, et al. Sympathetic nervous activation in obesity and the metabolic syndrome-causes, consequences and therapeutic implications. Pharmacol Ther. 2010;126(2):159-72.
33. Straznicky, N.E., et al., Baseline Sympathetic Nervous System Activity Predicts Dietary Weight Loss in Obese Metabolic Syndrome Subjects. J Clin Endocrinol Metab, 2011.
34. Schlaich MP, et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009;54(6):1195-201.
35. Schlaich MP, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009;20(5):933-9.
36. Straznicky, N.E., et al., Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome individuals. J Hypertens. 2011;29(3):553-64.
37. Jamerson KA, et al. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension. 1993;21 (5):618-23. (Pubitemid 23120215)
38. Rasio EA. Passage of glucose through the cell membrane of capillary endothelium. Am J Physiol. 1975;228(4):1103-7.
39. Grassi G, et al. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens. 2004;22(12):2363-9. (Pubitemid 39620287)
40. Egan BM. Neurohumoral, hemodynamic and microvascular changes as mechanisms of insulin resistance in hypertension: a provocative but partial picture. Int J Obes. 1991;15 Suppl 2:133-9.
41. Laakso M, et al. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest. 1990;85(6):1844-52. (Pubitemid 20192958)
42. Klag MJ, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334(1):13-8. (Pubitemid 26012498)
43. Rostand SG, et al. Cardiovascular complications in renal failure [editorial]. J Am Soc Nephrol. 1991;2(6):1053-62.
44. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339(12):799-805. (Pubitemid 28447453)
45. Coresh J, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2001;161(9):1207-16. (Pubitemid 32691517)
46. Tonelli M, et al. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis. 2001;37(3):484-9. (Pubitemid 32195286)
47. Lazarus JM, Hampers C, Merrill JP. Hypertension in chronic renal failure. Treatment with hemodialysis and nephrectomy Arch Intern Med. 1974;133(6):1059-66.
48. Ligtenberg G, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure [see comments]. N Engl J Med. 1999;340(17):1321-8. (Pubitemid 29196594)
49. Grassi G, et al. Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation. 1998;97(20):2037-42. (Pubitemid 28243666)
50. Narkiewicz K, et al. Baroreflex control of sympathetic nerve activity and heart rate in obstructive sleep apnea. Hypertension. 1998;32(6):1039-43. (Pubitemid 29001433)
51. Schobel HP, et al. Preeclampsia - a state of sympathetic overactivity [see comments]. N Engl J Med. 1996;335(20):1480-5. (Pubitemid 26376680)
52. Zoccali C, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105(11):1354-9. (Pubitemid 34260428)
53. Vonend O, et al. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens. 2003;21(9):1709-17. (Pubitemid 37076355)
54. Strojek K, et al. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol. 2001;12(3):602- 5. (Pubitemid 32180031)
55. Onesti G, et al. Blood pressure regulation in end-stage renal disease and anephric man. Circ Res. 1975;36(6 Suppl 1):145-52.
56. Getts RT, et al. Regression of left ventricular hypertrophy after bilateral nephrectomy. Nephrol Dial Transplant. 2006;21(4):1089- 91.
57. Schlaich MP, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108(5):560-5. (Pubitemid 36961170)
58. Hering D MF, Walton AS, Krum H, Lambert G, Lambert EA, Sobotka PA, Böhm M, Cremers B, Esler M, Schlaich MP. Renal denervation in moderate to severe chronic kidney disease. J Am Soc Nephrol. 2012;in press. This pilot study provides first evidence that renal denervation is safe and effective in patients with moderate to severe chronic kidney disease.
59. Brandt MC, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59(10): 901-9. This study demonstrates that renal denervation is not only associated with BP reduction but also with a marked regression of LV hypertrophy in patients with resistant hypertension.